Phaseline

Targets › IL6

IL6 (Interleukin-6): drug programs, companies and trials

13 programs from 13 companies in 20 trials: 12 Phase 2, 4 Phase 3, 3 Phase 1, 1 Phase 4; Oncology, Cardiovascular, Immunology; next expected readout Dec 2026.

Cytokine with a wide variety of biological functions in immunity, tissue regeneration, and metabolism. Binds to IL6R, then the complex associates to the signaling subunit IL6ST/gp130 to trigger the intracellular IL6-signaling pathway (Probable). (UniProt, P05231)

Open in Phaseline: the race on IL6, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Alaa Ashraf Muhammad HelalDiacerein
IL-6 inhibitor
IL6Phase 4Psoriasis VulgarisFeb 2027
Novo NordiskZiltivekimab
Interleukin-6 inhibitor; Interleukin-6 binding agent
IL6Phase 3Heart Failure; Cardiovascular Risk; Myocardial InfarctionJan 2027
R-PharmOlokizumab
Interleukin-6 inhibitor
IL6Phase 3Polymyalgia Rheumatica; Lung Diseases, Interstitial; Juvenile Idiopathic ArthritisApr 2027
Yuanquan YangSiltuximab
Interleukin-6 antagonist
IL6Phase 2Advanced Malignant Solid NeoplasmDec 2026
Sir Run Run Shaw HospitalIcaritin
Downregulates TNF-α, IL-6, and PD-L1 expression; reduces MDSC proportion to modulate tumor
TNF, IL6, PDCD1LG1Phase 2Advanced Pancreatic Ductal AdenocarcinomaApr 2027
Eli LillyClazakizumab (LY5724886)
Interleukin-6 inhibitor
IL6Phase 2AtherosclerosisMay 2027
Institute of Hematology & Blood Diseases Hospital, ChinaSiltuximab
Interleukin-6 antagonist
IL6Phase 2CRS - Cytokine Release SyndromeAug 2027
CSL BehringClazakizumab (CSL300)
Interleukin-6 inhibitor
IL6Phase 2End Stage Kidney Disease; End Stage Kidney Disease (ESKD); COVID-19 InfectionAug 2027
Tourmaline Bio, Inc., a Novartis CompanyPacibekitug (TOUR006)
Interleukin-6 inhibitor
IL6Phase 2Thyroid Eye DiseaseSep 2027
Memorial Sloan Kettering Cancer CenterSiltuximab
Interleukin-6 antagonist
IL6Phase 2Multiple MyelomaOct 2027
Massachusetts General HospitalSiltuximab
Interleukin-6 antagonist
IL6Phase 2SchwannomatosisNov 2027
Washington University School of MedicineSiltuximab
Interleukin-6 antagonist
IL6Phase 1Antibody Mediated Rejection of Lung TransplantDec 2027
Taylor BrooksSiltuximab
Interleukin-6 antagonist
IL6Phase 1Non-Hodgkin LymphomaSep 2028

Conditions

Multiple Myeloma (2) Antibody Mediated Rejection of Lung Transplant (1) Heart Failure (1) Cardiovascular Risk (1) Myocardial Infarction (1) End Stage Kidney Disease (1) End Stage Kidney Disease (ESKD) (1) COVID-19 Infection (1) Atherosclerosis (1) CRS - Cytokine Release Syndrome (1) Advanced Pancreatic Ductal Adenocarcinoma (1) Polymyalgia Rheumatica (1)

Modalities

antibody (8), small molecule (4), mixed (1)

Companies

Memorial Sloan Kettering Cancer Center (1) Washington University School of Medicine (1) Novo Nordisk (1) CSL Behring (1) Eli Lilly (1) Institute of Hematology & Blood Diseases Hospital, China (1) Sir Run Run Shaw Hospital (1) R-Pharm (1) Tourmaline Bio, Inc., a Novartis Company (1) Alaa Ashraf Muhammad Helal (1) Yuanquan Yang (1) Massachusetts General Hospital (1) Taylor Brooks (1)

Related targets

TNF (1) PDCD1LG1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.